Related Experiment Video
Updated: Mar 13, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines
I Nakachi1, B A Helfrich2, M A Spillman3
1Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Denver/Anschutz Medical Campus, Aurora, Colorado, USA.
Abstract:
Src kinase is recognized as a key target for molecular cancer therapy. However, methods to efficiently select patients responsive to Src inhibitors are lacking. We explored the sensitivity of ovarian cancer cell lines to the Src kinase inhibitor saracatinib to identify predictive markers of drug sensitivity using gene microarrays. Pituitary tumor transforming gene 1 (PTTG1) was selected as a potential biomarker as mRNA levels were correlated with saracatinib resistance, as well as higher PTTG1 protein expression. PTTG1 expression was correlated with proliferation, cell division, and mitosis in ovarian cancer tissues data sets. In sensitive cell lines, saracatinib treatment decreased PTTG1 and fibroblast growth factor 2 (FGF2) protein levels. Downregulating PTTG1 by siRNAs increased saracatinib sensitivity in two resistant cell lines. Our results indicate PTTG1 may be a valuable biomarker in ovarian cancer to predict sensitivity to saracatinib, and could form the basis of a targeted prospective saracatinib trial for ovarian cancer.
Insights
Pituitary tumor transforming gene 1 (PTTG1) may predict ovarian cancer response to the Src inhibitor saracatinib. Lower PTTG1 levels indicate sensitivity, suggesting PTTG1 as a biomarker for targeted therapy selection.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Src kinase is a critical target in molecular cancer therapy.
- Effective patient selection for Src inhibitor therapy remains a challenge.
- Ovarian cancer treatment requires novel therapeutic strategies and predictive biomarkers.
Purpose of the Study:
- To identify predictive biomarkers for saracatinib sensitivity in ovarian cancer.
- To investigate the role of Pituitary tumor transforming gene 1 (PTTG1) as a potential biomarker.
- To explore the correlation between PTTG1 expression and ovarian cancer cell line sensitivity to saracatinib.
Main Methods:
- Utilized gene microarrays to analyze ovarian cancer cell line sensitivity to saracatinib.
- Assessed PTTG1 mRNA and protein expression levels.
- Correlated PTTG1 expression with proliferation, cell division, and mitosis in ovarian cancer tissue datasets.
- Investigated the effect of PTTG1 downregulation using siRNAs on saracatinib sensitivity.
Main Results:
- PTTG1 mRNA levels correlated with saracatinib resistance.
- Higher PTTG1 protein expression was observed in resistant cell lines.
- Saracatinib treatment reduced PTTG1 and FGF2 protein levels in sensitive cell lines.
- Downregulating PTTG1 enhanced saracatinib sensitivity in resistant ovarian cancer cell lines.
Conclusions:
- PTTG1 is a potential predictive biomarker for saracatinib sensitivity in ovarian cancer.
- PTTG1 expression levels can guide patient selection for saracatinib therapy.
- These findings support the development of targeted prospective clinical trials for ovarian cancer patients receiving saracatinib.
